Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke by Sheetal Bodhankar et al.
ORIGINAL RESEARCH ARTICLE
published: 11 August 2014
doi: 10.3389/fncel.2014.00228
Targeting immune co-stimulatory effects of PD-L1 and
PD-L2 might represent an effective therapeutic strategy in
stroke
Sheetal Bodhankar 1,2 ,Yingxin Chen3, Andrew Lapato1,2 , Arthur A. Vandenbark1,2,4 ,
Stephanie J. Murphy3† and Halina Offner 1,2,3*
1 Neuroimmunology Research, Portland Veterans Affairs Medical Center, Portland, OR, USA
2 Department of Neurology, Oregon Health and Science University, Portland, OR, USA
3 Department of Anesthesiology and Perioperative Medicine, Oregon Health and Science University, Portland, OR, USA
4 Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR, USA
Edited by:
Arthur Liesz, University Hospital
Munich, Germany
Reviewed by:
Keith Pennypacker, University of
South Florida, USA
GregoryW. Konat,West Virginia
University, USA
*Correspondence:
Halina Offner, Neuroimmunology
Research, Portland Veterans Affairs
Medical Center, R&D-31, 3710 SW
US Veterans Hospital Road, Portland,
OR 97239, USA
e-mail: offnerva@ohsu.edu
†Present address:
Stephanie J. Murphy, Division of
Comparative Medicine, Ofﬁce of
Research Infrastructure Programs,
Division of Program Coordination,
Planning, and Strategic Initiatives,
Ofﬁce of the Director, National
Institutes of Health, Bethesda,
MD, USA
Stroke outcome is worsened by the inﬁltration of inﬂammatory immune cells into ischemic
brains. Our recent study demonstrated that PD-L1- and to a lesser extent PD-L2-deﬁcient
mice had smaller brain infarcts and fewer brain-inﬁltrating cells vs. wild-type (WT) mice,
suggesting a pathogenic role for PD-ligands in experimental stroke.We sought to ascertain
PD-L1 and PD-L2-expressing cell types that affect T-cell activation, post-stroke in the
context of other known co-stimulatory molecules. Thus, cells from male WT and PD-L-
deﬁcient mice undergoing 60 min of middle cerebral artery occlusion (MCAO) followed
by 96 h of reperfusion were treated with neutralizing antibodies to study co-stimulatory
and co-inhibitory interactions between CD80, cytotoxic T-lymphocyte antigen-4 (CTLA-4),
PD-1, and PD-Ls that regulate CD8+ and CD4+ T-cell activation. We found that antibody
neutralization of PD-1 and CTLA-4 signaling post-MCAO resulted in higher proliferation
in WT CD8+ and CD4+ T-cells, conﬁrming an inhibitory role of PD-1 and CTLA-4 on T-
cell activation. Also, CD80/CD28 interactions played a prominent regulatory role for the
CD8+ T-cells and the PD-1/PD-L2 interactions were dominant in controlling the CD4+ T-cell
responses in WT mice after stroke. A suppressive phenotype in PD-L1-deﬁcient mice was
attributed to CD80/CTLA-4 and PD-1/PD-L2 interactions. PD-L2 was crucial in modulating
CD4+ T-cell responses, whereas PD-L1 regulated both CD8+ and CD4+ T-cells.To establish
the contribution of PD-L1 and PD-L2 on regulatory B-cells (Bregs), infarct volumes were
evaluated in male PD-L1- and PD-L2-deﬁcient mice receiving IL-10+ B-cells 4h post-MCAO.
PD-L2- but not PD-L1-deﬁcient recipients of IL-10+ B-cells had markedly reduced infarct
volumes, indicating a regulatory role of PD-L2 on Bregs. These results imply that PD-
L1 and PD-L2 differentially control induction of T- and Breg-cell responses after MCAO,
thus suggesting that selective targeting of PD-L1 and PD-L2 might represent a valuable
therapeutic strategy in stroke.
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INTRODUCTION
Stroke is a leading cause of death and disability worldwide. The
most common type of stroke is ischemic stroke (87% of cases),
where an infarct develops after a fewminutes of ischemia (Lakhan
et al., 2009). Ischemic stroke is characterized by the disruption of
cerebral blood ﬂow (Dirnagl et al., 1999) and a timely restoration
of blood ﬂow (reperfusion) achieved by intravenous administra-
tion of tissue plasminogen activator within 4.5 h after stroke onset
remains the only approved treatment for limiting brain injury
following ischemic stroke. While on the one hand, reperfusion
of the ischemic brain is desirable, on the other it may lead to
tissue damage. Reperfusion is known to enhance the inﬂamma-
tory response and causes additional injury to adjacent brain tissue
(Schaller and Graf, 2004). Several factors have been described as
mediators of ischemia–reperfusion (I–R)-induced brain injury
(Iadecola and Anrather, 2011; Macrez et al., 2011). Although
the cells of the innate immune system, especially neutrophils
and monocytes, always seem to be in focus, recent studies
have demonstrated that T-cells also have an impact on tissue
damage.
In fact, several studies evaluating stroke outcome in T-
cell-deﬁcient mice have consistently reported a smaller infarct
volume and improved functional outcome than in wild-type
(WT) controls (Yilmaz et al., 2006; Hurn et al., 2007; Shichita
et al., 2009; Kleinschnitz et al., 2010). Studies also demon-
strate that mice lacking RANTES (CCL5), a chemokine that
recruits T-cells (as well as other immune cells) into inﬂam-
matory sites (Appay and Rowland-Jones, 2001), have smaller
infarct volumes than WT mice, again attributing a pathogenic
role to the T-cells. However, the mechanisms of T-cell-mediated
brain injury following stroke remain unclear. It is also not
known whether the activation of T-cells follows the classical
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antigen-dependent pathway or if the inﬁltration into the brain
following stroke is too rapid to follow the classical path-
way.
The classical antigen-dependent activation of naive T-cells
comprises two main steps (Abbas, 2011). The ﬁrst step involves
the binding of the T-cell receptor (TCR) to the antigen pre-
sented on the major histocompatability complex on the surface
of an antigen-presenting cell (APC). The second step involves
the binding of co-stimulatory molecules on the T-cell and the
APC, such as CD28 on the T-cell and CD80 (B7.1) and CD86
(B7.2) on the APC (Santana and Rosenstein, 2003). This second
step involving co-receptor signaling is an important mechanism
for coordinating and tightly regulating immune responses. Co-
stimulation via ligation of the co-receptor CD28 on T-cells by
B7 molecules on APCs is required for optimal T-cell activation
(Linsley et al., 1991). Once mobilized, however, T-cells begin to
express other members of the CD28/B7 receptor families that
attenuate the immune response through inhibition of prolifer-
ation and cytokine production (Peggs et al., 2009). Among the
negative signaling molecules, cytotoxic T-lymphocyte antigen-
4 (CTLA-4) and PD-1 belonging to the CD28/B7 families, are
the most studied. CTLA-4 is rapidly up-regulated following T-
cell activation and binds to B7 molecules (Curran et al., 2010).
PD-1 (CD279 in CD nomenclature) is expressed on activated
T and B cells as well as on activated myeloid cells and both
these co-receptors elicit inhibitory signals upon co-ligation with
the TCR and play a role in the control of tolerance (Ishida
et al., 1992; Agata et al., 1996; Greenwald et al., 2005). Two PD-
1 ligands have thus far been described, PD-L1 also named as
B7-H1 (CD274), and PD-L2 also named as B7-DC (CD273;
Dong et al., 1999; Latchman et al., 2001). The expression of
PD-L1 within non-lymphoid tissues suggests that it may reg-
ulate the function of self-reactive immune cells in peripheral
tissues and thus, may regulate inﬂammatory responses (Keir
et al., 2006). In addition to PD-1, studies have demonstrated
that PD-L1 also interacts with CD80 in both mice and humans
(Butte et al., 2007, 2008). Both PD-L1 and PD-L2 inhibit T-cell
proliferation, cytokine production and cell adhesion (Latchman
et al., 2001; Saunders et al., 2005), although some contradic-
tory data have suggested a co-stimulatory function (Dong et al.,
1999).
Prior research from our laboratory, performed using PD-1−/−
mice, demonstrated the inhibitory effects of PD-1 in stroke
because when MCAO was compared to WT male mice after 96 h
of reperfusion, cortical, striatal, and total infarct volumes were
signiﬁcantly larger in PD-1−/− mice, with a marked recruitment
of inﬂammatory cells from the periphery into the central ner-
vous system (CNS; Ren et al., 2011). Studies were then extended to
investigate the role of the PD-ligands, PD-L1 and PD-L2, in mod-
ulating severity of ischemic brain injury and the associated CNS
inﬂammation. Contrary to our expectations, PD-L1-deﬁcient
(PD-L1−/−) and PD-L2-deﬁcient (PD-L2−/−) mice that were
similarly subjected to 60 min of MCAO followed by 96 h of
reperfusion demonstrated smaller total infarct volumes compared
to WT mice (Bodhankar et al., 2013). The immune parameters
matched the stroke outcome in that the PD-L1−/−, and to a lesser
extent PD-L2−/− mice, had reduced levels of proinﬂammatory
activated microglia and/or inﬁltrating monocytes and CD4+ T-
cells in the ischemic hemispheres, thus suggesting a pathogenic
rather than a regulatory role for both PD-ligands. Knowing that
T-cell inﬂux is highly time-dependent, amore thorough character-
izationof the temporal proﬁle of variousT-cell subsetswas needed.
Therefore, discerning themechanisms that lead toT-cell activation
in the periphery and subsequent proliferation andmobilization of
T-cells into the CNS is a very critical determinant in ischemic
stroke outcome.
Hence, the aim of the current study was to assess the contribu-
tion of the various co-stimulatory molecules in controlling T-cell
proliferation as well as to verify the PD-L-expressing cell-types
responsible for mediating its central effects after MCAO. For this
purpose, T-cells obtained from WT, PD-L1−/− and PD-L2−/−
mice were carboxyﬂuorescein succinimidyl ester (CFSE)-labeled
and co-cultured with APCs in the presence of various neutralizing
antibodies (Abs) to co-stimulatory receptors. Our results demon-
strate that antibody neutralization of PD-1 and CTLA-4 signaling
after MCAO resulted in higher proliferation levels in WT CD8+
and to a lesser extent CD4+ T-cells, conﬁrming an inhibitory role
of PD-1 and CTLA-4 on T-cell activation. Conversely, antibody
neutralizing of CD80 and PD-L1 after MCAO resulted in reduced
proliferation, indicating a stimulatory role of CD80 and PD-L1
in WT mice on T-cell activation. Interestingly, the CD80/CD28
interactions appeared to play a prominent regulatory role for the
CD8+ T-cells while the PD-1/PD-L2 interactions were dominant
in controlling the CD4+ T-cell responses inWTmice, after stroke.
The suppressive phenotype in PD-L1 deﬁcientmice was attributed
to CD80/CTLA-4 and PD1/PD-L2 interactions. PD-L2was crucial
in modulating CD4+ T-cell responses, whereas PD-L1 predomi-
nantly regulated CD8+ T-cells. To establish the contribution of
PD-L1 and PD-L2 on regulatory B-cells (Bregs), infarct volumes
were evaluated inmalePD-L1- andPD-L2-deﬁcientmice receiving
IL-10+ B-cells 4 h after MCAO. PD-L2- but not PD-L1-deﬁcient
recipients of IL-10+ B-cells hadmarkedly reduced infarct volumes,
indicating a regulatory role of PD-L2 on Bregs. These results imply
that PD-L1 and PD-L2 differentially control induction of T- and
Breg-cell responses after MCAO.
MATERIALS AND METHODS
ANIMALS
PD-L1-deﬁcient (PD-L1−/−) and PD-L2-deﬁcient (PD-L2−/−)
mice on the C57BL/6 background were gifts from Indira Guleria,
PhD (Transplantation Research Center, Brigham and Women’s
Hospital, Children’s Hospital Boston, and Harvard Medical
School, Boston,MA, USA) and Arlene Sharpe, Ph.D (Department
of Pathology, HarvardMedical School, Boston,MA,USA), respec-
tively. Based on Dr. Guleria’s and Dr. Sharpe’s recommendations
and previous publications (Keir et al., 2006; Zhang et al., 2010),
age-matched 8–12-week-old male were used. WT C57BL/6J mice
were obtained from Jackson Laboratory, Bar Harbor, ME, USA.
Animals were randomized to treatment groups. All experiments
were performed in accordance with National Institutes of Health
(NIH) guidelines for the use of experimental animals, and the pro-
tocols were approved by Portland Veteran Affairs Medical Center
and Oregon Health & Science University Animal Care and Use
Committees.
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MIDDLE CEREBRAL ARTERY OCCLUSION (MCAO) MODEL
All surgeries were conducted under aseptic conditions by a single
surgeon. Transient focal cerebral ischemia was induced in male
PD-L1−/−, PD-L2−/−, and WT mice for 60 min by reversible
right MCAO under isoﬂurane anesthesia followed by 96 h of
reperfusion as previously described (Chen et al., 2012). Head and
body temperatures were controlled at 36.5 ± 1.0◦C before, dur-
ing, and after MCAO with warm water pads and a heating lamp.
The common carotid artery was temporarily occluded and a 6-
0 nylon monoﬁlament surgical suture (Ethicon, Somerville, NJ,
USA) with a silicone-coated (Xantopren Comfort Light, Heraeus,
Hanau, Germany) tip was inserted via an external carotid artery
stump distal to the internal carotid artery to the origin of the
middle cerebral artery. After 60 min of MCAO, reperfusion was
initiated by intraluminal ﬁlament withdrawal and the incision was
closed with 6-0 surgical sutures (Ethicon). Each animal was then
awakened and recovered in a separate cage with a warmwater pad.
In sham-treatedmice, the ﬁlament was placed but not advanced to
achieve MCAO. Occlusion and reperfusion were veriﬁed in each
animal by laser Doppler ﬂowmetry (LDF; Model DRT4, Moor
Instruments, Wilmington, DE, USA). Animals were excluded if
intra-ischemicLDF (percentage of pre-ischemicLDFbaseline)was
greater than 30%. Neurological deﬁcit scores were determined at
1, 24, 48, 72, and 96 h of reperfusion to conﬁrm ischemia and the
presence of ischemic injury using a 0 to 4-point scale as follows: 0,
no neurological dysfunction; 1, failure to extend left forelimb fully
when lifted by tail; 2, circling to the contralateral side; 3, falling
to the left; and 4, no spontaneous movement or in a comatose
state (Chen et al., 2012). The surgeon was not blinded to the ani-
mal genotypes. However, the surgeon was blinded to treatment
groups.
CELL ISOLATION
Splenocyte suspensions were prepared in Roswell Park Memorial
Institute (RPMI) 1640 bymechanical disruption followedbyuse of
red cell lysis buffer (eBioscience, SanDiego,CA,USA) according to
the manufacturer’s instructions. The cells were washed twice with
RPMI-1640, counted, and resuspended in stimulation medium
containing 2% fetal bovine serum (FBS; HyClone, GE Healthcare,
UT, USA).
PURIFICATION AND ISOLATION OF T-CELLS
T-cells from splenocytes of MCAO-subjected WT, PD-L1−/−
and PD-L2−/− mice were puriﬁed using paramagnetic bead-
conjugated Abs from the pan T-cell isolation kit II and
subsequently separated by AutoMACS (Miltenyi Biotec, Auburn,
CA, USA), according to manufacturer’s instructions. The purity
of the negative fraction of cells thus separated (CD3+ T-cells)
was examined by ﬂow cytometry. Cell preparations demonstrating
>98% purity of each cell type were used for co-culture studies.
CFSE LABELING AND T-CELL PROLIFERATION ASSAY
Sorter-puriﬁed T-cells were washed twice in PBS, labeled with
2.5 μM CFSE (Molecular Probes, Eugene, OR, USA), for 7 min
at 37◦C and quenched with stimulation medium containing 10%
FBS. Cells were washed twice in stimulation medium contain-
ing 2% FBS before they were plated for the proliferation assay.
CFSE-labeled puriﬁedT-cells (1× 105/well)were co-culturedwith
unlabeled non-T-cells (1 × 105/well) in 96-well plates and were
incubated in the presence of anti-CD3 Ab [2.5 μg/mL; baseline
condition (puriﬁed hamster anti-mouse CD3ε; clone 145-2C11)]
for 72 h. Functional grade puriﬁed neutralizing Abs to CD80
(clone 16-10A1), CD152 (CTLA-4, clone 9H10), CD279 (PD-1;
clone RMP1-14), CD274 (PD-L1; clone MIH5), CD273 (PD-
L2, clone TY25), and CD28 (clone 37.51) were used at a ﬁnal
concentration of 10 μg/mL, alone or in combination with other
neutralizing Abs (eBioscience, San Diego, CA, USA). Proper neg-
ative control conditions such as T-cells + non T-cells with no
anti-CD3 Ab and non-CFSE-labeled T-cells were also included.
Each culture condition was plated in triplicate (or in some cases
where very few splenocytes were acquired after stroke, in dupli-
cate). After 3 days, CD8+ and CD4+ T-cell proliferation was
assessed based on CFSE dilution and analyzed by ﬂow cytometry.
Each experiment was repeated at least twice.
Inhibition of T-cell proliferation in the presence of non-T-cells
was calculated from the following formula:
Stimulation index (SI)= [percent proliferating cells in presence
of neutralizing Ab] – [percent expression at baseline]/[percent
expression at baseline].
CELL SORTING AND ADOPTIVE TRANSFER OF B-CELLS
Male IL-10 GFP reporter mice served as donors of B-cells. Splenic
CD19+ B-cells were puriﬁed using paramagnetic bead-conjugated
Abs from the CD19 cell isolation kit and subsequently separated
by AutoMACSTM (Miltenyi Biotec, Auburn, CA, USA). The neg-
ative fraction of the cells thus separated were CD19+ B-cells with
a purity of ≥94%. CD19+ B-cells were suspended in RPMI 1640
medium with 2% FBS and cultured in the presence of 1 μg/mL
lipopolysaccharide (LPS,Escherichia coli strain K12) for 48 h. After
48 h of culture, B-cells were harvested from culture plates, washed
free of LPS and viable cells were counted using a hemocytometer
with the trypan blue exclusion method. Five million puriﬁed IL-
10-GFP+ B-cells from the donor mice were suspended in 100 μL
RPMI 1640 medium and were transferred intravenously (i.v.) into
PDL1−/− and PD-L2−/− mouse experimental groups 4 h after
MCAO. Each PDL1−/− and PD-L2−/− mouse received either
5 × 106/100 μL puriﬁed IL-10-GFP+ B-cells or 100 μL RPMI
1640 medium (control group).
INFARCT VOLUME ANALYSIS
The individual performing infarct volume analysiswas not blinded
to genotype but was blinded to the treatment groups. Mice
were euthanized and brains collected at 96 h of reperfusion
for 2,3,5-triphenyltetrazolium chloride histology and then digi-
tal image analysis of infarct volume was undertaken as previously
published (Chen et al., 2012). Images were analyzed using Sig-
maScan Pro 5.0 (Systat Software, Inc., Point Richmond, CA,
USA). To control for edema, regional infarct volume (cor-
tex, striatum, and hemisphere) was determined by subtraction
of the ipsilateral non-infarcted regional volume from the con-
tralateral regional volume. This value was then divided by the
contralateral regional volume and multiplied by 100 to yield
regional infarct volume as a percentage of the contralateral
region.
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ANALYSIS OF CELL POPULATIONS BY FACS
The individual performing FACS analysis was not blinded to geno-
type. Anti-mouse Abs CD4 (GK1.5, BD Pharmingen, Franklin
Lakes, NJ, USA) and CD8 (53-6.7, BD Pharmingen) were used for
the proliferation assay. Anti-mouse CD19 (1D3, BD Pharmingen),
CD1d (1B1, BD Pharmingen), CD5 (53-7.3, BD Pharmingen),
CD28 (37.51, BD Pharmingen), CD152 (CTLA-4, UC10-4B9),
ICOS (C398-4A, BD Pharmingen), PD-L1 (MIH5, eBioscience),
andPD-L2 (TY25, eBioscience)wereused for this study. Single-cell
suspensions were washed with staining medium (PBS containing
0.1%NaN3 and 2%FCS). After incubationwithmAb andwashing
with staining buffer, propidium iodide (PI) was added to identify
dead cells. FACS data acquisition was performed on a FACSCal-
ibur ﬂow cytometer (BD Biosciences, San Jose, CA,USA) and data
were analyzed using isotype control Abs to set quadrants before
calculating the percentage of positive cells, using FCS Express (De
Novo Software, Los Angeles, CA, USA).
INTRACELLULAR STAINING
Intracellular staining was visualized using a published
immunoﬂuorescence protocol (Subramanian et al., 2011). Brieﬂy,
2 × 106 cells/mL were resuspended in complete medium (RPMI-
1640 containing 10% FCS, 1 mM/L pyruvate, 200 μg/mL
penicillin, 200 U/mL streptomycin, 4 mM/L L-glutamine, and
5 × 10−5 mol/L 2-β-ME), with PMA (50 ng/mL), ionomycin
(500 ng/mL), and Brefeldin A (10 μg/mL, Sigma–Aldrich) for
4 h. For intracellular IL-10 detection, a modiﬁcation was fol-
lowed for the immunoﬂuorescence stainingprotocol (Yanaba et al.,
2008). Brieﬂy, isolated leukocytes or puriﬁed cells were resus-
pended (2 × 106 cells/mL) in complete medium and cultured
with LPS (10 μg/mL) in addition to PMA (50 ng/mL), iono-
mycin (500 ng/mL), and Brefeldin A (10 μg/mL; all reagents
from Sigma-Aldrich) for 4 h. Fc receptors were blocked with
anti-FcR mAb (2.3G2, BD Pharmingen) before cell surface stain-
ing, ﬁxed, and permeabilized with the Fixation/Permeabilization
buffer (eBioscience), according to the manufacturer’s instruc-
tions. Permeabilized cells were washed with 1× Permeabilization
Buffer (eBioscience) and stained with APC-conjugated anti-IL-
10 mAb (JES5-16E3, eBioscience). Isotype matched mAb served
as negative controls to demonstrate speciﬁcity and to establish
background IL-10 staining levels.
STATISTICAL ANALYSIS
All values are reported as mean ± SEM. For ﬂow data analysis and
representation of three and more groups, the one-way ANOVA
followed by post hoc Tukey’s test was applied. For the prolifer-
ation assay, the one-way ANOVA with Dunnett’s post hoc test
to compare all neutralizing Ab conditions to just the anti-CD3
Ab treated (Control) value was applied. Statistical analyses were
performed using GraphPad PRISM software version 5 (La Jolla,
CA, USA). For all tests, p values ≤0.05 were considered statisti-
cally signiﬁcant. Signiﬁcant differences are denoted as ∗p ≤ 0.05;
∗∗p ≤ 0.01; ∗∗∗p ≤ 0.001. Differences in cortical, striatal, and
hemispheric (total) infarct volumes were determined by one-way
ANOVA with post hoc Newman–Keul’s test. Statistical signiﬁ-
cance was p < 0.05. Statistical analyses for infarct volumes were
performed using SigmaStat Statistical Software, Version 3.1 (SPSS
Inc., Chicago, IL, USA).
RESULTS
CD80/CD28 INTERACTIONS PROMINENTLY REGULATE CD8+ T-CELLS,
WHILE PD-1/PD-L2 CONTROL THE CD4+ T-CELL RESPONSES IN WT
MICE SUBJECTED TO MCAO
Over the past few years, our laboratory has demonstrated an
inhibitory role for PD-1 in ischemic stroke (Ren et al., 2011), but
on the contrary, a co-stimulatory role for PD-L1 and to a lesser
extent PD-L2 (Bodhankar et al., 2013). To clarify these ﬁndings,
it was important to discern which combinations of the major co-
stimulatory molecules and their known binding partners might
contribute to stroke outcome.
Though the PD-1/PD-L pathway is important in governing
T-cell activation and proliferation, it is not the only deter-
minant pathway. Hence, to assess the role played by various
other co-stimulatory pathways potentially involved in T-cell acti-
vation/proliferation after MCAO, neutralizing Abs were used.
However, to narrow down the combinations of neutralizing Abs
needed, we ﬁrst identiﬁed key players in the co-stimulatory path-
way on splenocytes fromWT mice subjected to 60 min of MCAO
followed by 96 h of reperfusion in comparison with sham mice.
As demonstrated in Figure 1A, the expression of the positive
co-stimulatory molecule, CD28, was signiﬁcantly increased on
CD4+ T-cells after MCAO, with a similar trend for its increased
expression on CD8+ T-cells. On the other hand, the expression
of the negative co-stimulatory molecule, CTLA-4, which opposes
the actions of CD28-mediated co-stimulation (Greenwald et al.,
2005), was signiﬁcantly down regulated both on CD4+ and CD8+
splenic T-cells (Figure 1B).We also determined the expression lev-
els of ICOS, which is known to synergize with CD28 to promote
the activation of T-cell responses (Greenwald et al., 2005). How-
ever, no difference in the level of expression of ICOS as compared
to the shamMCAO-subjectedWT splenocytes, was demonstrated
(Figure 1C).
Furthermore, neutralizing Abs to the classic B7/CD28,
B7/CTLA-4, and the PD-1/PD-L co-stimulatory receptors were
evaluated in WT mice subjected to 60 min MCAO followed
by 96 h of reperfusion. Splenocytes from MCAO-subjected WT
mice were obtained and total T-cells, sorted by negative selec-
tion, were labeled with CFSE. These labeled T-cells were then
co-cultured with APCs in the presence of different combina-
tions of neutralizing Abs to various co-stimulatory molecules.
After 72 h of co-culture, the CD8+ and CD4+ T-cell prolif-
erative capacities were determined by CFSE dilution by ﬂow
cytometry. As demonstrated in Figure 2A, proliferation of CD8+
T-cells, post MCAO, was signiﬁcantly reduced in the presence
of anti-CD80 Ab (p ≤ 0.05), and more so when both anti-
CD28 and anti-CD80 Abs were used in combination (p ≤ 0.01).
There was also a trend towards decreased proliferation using anti-
PD-L1 and anti-CD28 Abs, individually and in combination,
although the changes were not signiﬁcant. These changes indi-
cate a positive role for the CD28/CD80 co-stimulatory molecules
in promoting CD8+ T-cell proliferation in WT mice subjected
to MCAO. On the other hand, neutralizing PD-1 led to a sig-
niﬁcant increase (p ≤ 0.05) in proliferation of CD8+ T-cells.
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Similarly, neutralizing only PD-L2 or CTLA-4 led to nominally
but not signiﬁcantly increased proliferation of CD8+ T-cells.
Thus, only PD-1 could be clearly implicated as a negative
regulator of CD8+ T-cell proliferation in MCAO-subjected WT
mice.
Interestingly, a different pattern of proliferative capacities was
demonstrated for CD4+ T-cells as compared to the CD8+ T-cells
obtained from theWTmice in response to various neutralizingAbs
(Figure 2B). TheCD4+ T-cells also demonstratednominally lower
proliferative capacities in the presence of anti-CD80 and anti-PD-
L1 neutralizing Abs, but there were no combinations tested that
produced signiﬁcantly reduced responses and thus the identiﬁca-
tion of a single set of co-stimulatory molecules. The CD4+ T-cells
had signiﬁcantly increased proliferation responses in the presence
of anti-PD-1 alone or in combination with anti-PD-L2 but not
anti-PD-L1 neutralizing Abs. Thus to summarize, CD28/CD80
interactions appear to play a prominent co-stimulatory role in
proliferation of WT CD8+ but not CD4+ T-cells, whereas PD-
1 functions as a negative regulator of both CD8+ and CD4+
T-cell proliferation in MCAO-treated mice. However, this reg-
ulation is permitted by co-expression of PD-L2 but not PD-L1,
thus implicating a PD-1/PD-L2 co-inhibitory pathway for CD4+
T-cell proliferation in MCAO.
NEUTRALIZING THE MAJOR CO-STIMULATORY MOLECULES IN THE
PD-L1−/− MICE, SUBJECTED TO MCAO, LEADS TO AN INCREASE IN
BOTH CD8+ AND CD4+ T-CELL PROLIFERATIVE CAPACITIES,
INDICATING AN OVERALL SUPPRESSIVE PHENOTYPE
Our previous work demonstrated a more signiﬁcant reduction in
infarct volumes in PD-L1−/− vs. PD-L2−/− mice as compared
to the WT mice (Bodhankar et al., 2013). Therefore, it was cru-
cial to decipher the contributing co-stimulatorymolecules leading
to a suppressive phenotype in the absence of PD-L1. Total T-
cells were puriﬁed from the spleens of PD-L1−/− mice, labeled
FIGURE 1 | Characterization of co-stimulatory molecules onT-cells of
WT splenocytes, post-MCAO. Splenocytes from sham- and
MCAO-subjected WT mice were harvested 96 h after MCAO (60 min) and
assessed for expression of: (A) CD28; (B) CTLA-4; and (C) ICOS on gated
CD4+ and CD8+ T-cells. Values represent mean numbers (±SEM) of
indicated cell subsets, gated on live leukocytes (by PI exclusion), from 4–5
mice of each group, from two separate experiments. Statistical analysis
was performed using Student’s t-test. Signiﬁcant differences between
sample means are indicated as *p ≤ 0.05 as compared to the sham-treated
WT mice.
with CFSE and co-cultured with APCs in presence of neutral-
izing Abs to various co-stimulatory molecules for 72 h. In the
absence of PD-L1 as in WT mice, the CD8+ T-cells exhibited sig-
niﬁcantly enhanced proliferationwith anti-PD-1 (p≤ 0.05) as well
as the combination of anti-PD-1 + anti-PD-L2 Abs (p ≤ 0.05;
Figure 3A). These results suggest involvement of PD-1/PD-L2
interactions and provide further support for the lack of regulatory
PD-1/PD-L1 interactions. Moreover, anti-CTLA-4 (p ≤ 0.001)
also promoted CD8+ T-cell proliferation, thus suggesting emer-
gence of this co-inhibitory molecule in the absence of PD-L1.
Importantly, neutralizing CD28 and CD80 alone or in combina-
tion did not result in loss of CD8+ T-cell proliferation as in WT
mice, thus suggesting that PD-L1 expression enables CD28/CD80
co-stimulation. Use of neutralizing Abs also had a remarkably
pronounced effect on the splenic CD4+ T-cells obtained from the
MCAO-subjected PD-L1−/− mice (Figure 3B). In the absence
of PD-L1, neutralizing PD-1 and PD-L2 receptors, individually
(p ≤ 0.01 and p ≤ 0.05, respectively) as well as in combination
(p ≤ 0.01), demonstrated a signiﬁcant increase in proliferative
capacities. Also a signiﬁcant increase in proliferation was observed
by neutralizing just CTLA-4 (p ≤ 0.001) and the combination of
CTLA-4+CD80 (p ≤ 0.01). These results re-conﬁrm a regulatory
role for the PD-1/PD-L2pathway and aswell, establish a regulatory
function for the CTLA-4/CD80 pathway that may emerge in the
absence of PD-L1.
FIGURE 2 | CD80/CD28 interactions prominently regulate CD8+ T-cells,
while PD-1/PD-L2 control the CD4+ T-cell responses inWT mice
subjected to MCAO.T-cells were puriﬁed, by negative sort, from the
spleens of MCAO-subjected WT mice, by labeling with speciﬁc microbeads
and separating on the AutoMACSTM.The puriﬁedT-cells were CSFE-labeled
and then cultured with non-T-cells from the same mice at a 1:1 ratio (T:APC)
in the presence of anti-CD3 antibody (2.5 μg/mL; baseline) and other
neutralizing Abs (10 μg/mL) to co-stimulatory molecules, in 96-well plates.
After 72 h of culture, cells were washed and evaluated by FACS Calibur for
(A) CD8+ and (B) CD4+ T-cell expression and CFSE dilution. Data
represent the stimulation indices of the CD8 and CD4T-cells in the
presence of neutralizing Abs as compared to the control (T:APC + anti-CD3
Ab) condition). The data are represented such that the baseline value is 1
and all other values are adjusted relative to the baseline. Data presented
are representative of splenocytes obtained from nine WT mice, with least
three separate experiments and each experiment comprising duplicates or
triplicates of the given neutralizing Ab condition. Signiﬁcant differences
between sample means are indicated as *p ≤ 0.05, **p ≤ 0.01 as
compared to the baseline condition.
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FIGURE 3 | Neutralizing the major co-stimulatory molecules in
PD-L1−/− mice, subjected to MCAO, leads to an increase in both
CD8+ and CD4+ T-cell proliferative capacities, indicating an overall
suppressive phenotype.T-cells were puriﬁed, by negative sort, from the
spleens of MCAO-subjected PD-L1−/− mice, by labeling with speciﬁc
microbeads and separating on the AutoMACSTMTM.The puriﬁedT-cells
were CSFE-labeled and then cultured with non-T-cells from the same mice
at a 1:1 ratio (T:APC) in the presence of anti-CD3 antibody (2.5 μg/mL;
baseline) and other neutralizing Abs (10 μg/mL) to co-stimulatory
molecules, in 96-well plates. After 72 h of culture, cells were washed and
evaluated by FACS Calibur for (A) CD8+ and (B) CD4+ T-cell expression and
CFSE dilution. Data represent the stimulation indices of the CD8 and CD4
T-cells in the presence of neutralizing Abs as compared to the control
[(T:APC + anti-CD3 Ab) condition]. The data are represented such that the
baseline value is 1 and all other values are adjusted relative to the baseline.
Data presented are representative of splenocytes obtained from six
PD-L1−/− mice, with least three separate experiments and each
experiment comprising duplicates or triplicates of the given neutralizing Ab
condition. Signiﬁcant differences between sample means are indicated as
*p ≤ 0.05, ** p ≤ 0.01 and ***p ≤ 0.001 as compared to the baseline
condition.
When similar studies were conducted using splenocytes from
MCAO-subjected PD-L2−/− mice, the responses, although more
subtle, strongly support results obtained fromWT and PD-L1−/−
mice. In the absence of PD-L2, proliferation of CD8+ T-cells was
diminished by treatmentwith neutralizing anti-CD28Ab andwith
the combination of anti-CD28 + anti-CD80 Abs (p ≤ 0.01 for
each, Figure 4A), again implicating CD28/CD80 as the major co-
stimulatory pathway that is enabled by co-expression of PD-L1.
Similarly, CD4+ T-cells demonstrated signiﬁcantly decreased pro-
liferative responses with anti-CD28 Ab alone (p ≤ 0.01) and with
the combination of anti-CD28+ anti-CD80Abs (p≤ 0.05).More-
over, the proliferation response of CD4+ T-cells was inhibited by
treatment with the combination of anti-CTLA-4+ anti-CD80Abs
(p≤ 0.01,Figure 4B), thus implicating a new co-stimulatory path-
way that emerged in the absence of PD-L2. Notably, in the absence
of PD-L2, there was no signiﬁcant neutralization of any tested
co-inhibitory molecules, particularly PD-1, thus conﬁrming the
requirement for PD-L2 in co-inhibitory regulation of proliferation
responses for both CD4+ and CD8+ T-cells.
In summary, these results demonstrate a dominant role for PD-
L1 in promoting CD8+ and CD4+ T-cell proliferation that con-
tributes to increased infarct volumes in mice subjected to MCAO.
Our data demonstrate that the presence of PD-L1 promotes the
CD28/CD80 co-stimulatory pathway, whereas its absence obviates
FIGURE 4 | Subtle changes in the proliferative capacities in the
PD-L2−/− mice indicate a minor role of PD-L2 in ischemic stroke.
T-cells were puriﬁed, by negative sort, from the spleens of
MCAO-subjected PD-L2−/− mice, by labeling with speciﬁc microbeads
and separating on the AutoMACSTM.The puriﬁedT-cells were CSFE-labeled
and then cultured with non-T-cells from the same mice at a 1:1 ratio (T:APC)
in the presence of anti-CD3 antibody (2.5 μg/mL; baseline) and other
neutralizing Abs (10 μg/mL) to co-stimulatory molecules, in 96-well plates.
After 72 h of culture, cells were washed and evaluated by FACS Calibur for
(A) CD8+ and (B) CD4+ T-cell expression and CFSE dilution. Data represent
the stimulation indices of the CD8 and CD4T-cells in the presence of
neutralizing Abs as compared to the control (T:APC+anti-CD3 Ab)
condition). The data are represented such that the baseline value is 1 and all
other values are adjusted relative to the baseline. Data presented are
representative of splenocytes obtained from seven PD-L2−/− mice, with
at least three separate experiments and each experiment comprising
duplicates or triplicates of the given neutralizing Ab condition. Signiﬁcant
differences between sample means are indicated as *p ≤ 0.05, **p ≤ 0.01
as compared to the baseline condition.
co-stimulation and allows full expression of the PD1/PD-L2 co-
inhibitory pathway as well as the emergence of the otherwise silent
CTLA-4/CD80 co-inhibitory pathway, both of which regulate T-
cell proliferation inmice subjected toMCAO. In contrast, presence
of PD-L2 is required for all co-inhibitory activity, whereas its
absence not only reduces expression of the major CD28/CD80
co-stimulatory pathway, but also allows emergence of a second
CTLA-4/CD80 co-stimulatory pathway for CD4+ T-cells.
PRESENCE OF PD-L1 ON APCs IS AS IMPORTANT AS IT IS ON T-CELLS,
WHILE EXPRESSION OF PD-L2 IS CRUCIAL ON APCs OF WT MICE
SUBJECTED TO MCAO
PD-L1 and PD-L2 are the two known ligands for PD-1 (Keir
et al., 2008), mostly expressed by APCs. However, they have differ-
ent expression patterns (Ishida et al., 2002; Yamazaki et al., 2002;
Ansari et al., 2003; Iwai et al., 2003; Liang et al., 2003; Salama et al.,
2003; Wiendl et al., 2003; Zhong et al., 2007; Keir et al., 2008).
Hence, we further investigated the effects on T-cell prolifera-
tion of the expression of PD-L1 and PD-L2 on APC and T-cells
obtained frommice post-MCAO.Thus, T-cellswere obtained from
MCAO-subjected WT mice and labeled with CFSE. To determine
if the presence of the PD-ligands is crucial for the antigen pre-
senting cells to inﬂuence the proliferative capacities of the T-cells,
APCs (non-T-cells) were obtained either from MCAO-subjected
PD-L1−/− or PD-L2−/− mice. The WT T-cells and PD-ligand
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knockout APCs were co-cultured in the presence of various neu-
tralizing Abs to co-stimulatory molecules. As demonstrated in
Figure 5A, there was a signiﬁcant decrease inCD8+ T-cell prolifer-
ationuponusing anti-PD-1 (onAPCand/orT-cells)+ anti-PD-L1
(T-cells only) and anti-CD80 (on APC and/or T-cells) + anti-PD-
L1 (on T-cells only) Abs (p ≤ 0.05 and p ≤ 0.01, respectively) and
a similar signiﬁcant decrease was demonstrated when just anti-
CD80 (on APC and/or T-cells) Ab (p ≤ 0.05) was used. Based
on availability of PD-L1, it follows that the effects of anti-PD-
L1 are restricted to the PD-L1+ T-cells (not on PD-L1−/− APC),
whereas effects of the anti-PD-1 and anti-CD80 Abs could be on
the APC or T-cells. It is thus possible that the inhibition of pro-
liferation of CD8+ T-cells involves Ab blockade of PD-1 and/or
CD80 expressed onAPCandPD-L1 expressed only onT-cells. This
conceivably could pair CD80/PD-L1 as a possible co-stimulatory
pathway for CD8+ T-cell proliferation that might be operative
in the absence of PD-L1 on APC. Pairing of PD-1/PD-L1 seems
unlikely due to many reports to the contrary. Surprisingly, there
was a signiﬁcant increase in proliferation of CD8+ T-cells when
anti-CD80 + anti-CTLA-4 Abs were used (p ≤ 0.01), possibly
suggesting a redundant co-inhibitory pathway involving CTLA-4
that might appear in the absence of PD-L1 on APC. However, the
increased CD8+ proliferation response after treatment ofWT cells
with anti-PD-1 (Figure 2A)wasnot apparent in the absence of PD-
L1 on APC. Similarly, in the CD4+ T-cells, besides the signiﬁcant
FIGURE 5 | Presence of PD-L1 onAPCs is as important as it is onT-cells,
while expression of PD-L2 is crucial on APCs ofWT mice subjected to
MCAO.T-cells were puriﬁed, by negative sort, from the spleens of
MCAO-subjected WT mice, by labeling with speciﬁc microbeads and
separating on the AutoMACSTM.The puriﬁedT-cells were CSFE-labeled and
then cultured with non-T-cells from PD-L1−/− mice at a 1:1 ratio (T:APC) in
the presence of anti-CD3 antibody (2.5 μg/mL; baseline) and other
neutralizing Abs (10 μg/mL) to co-stimulatory molecules, in 96-well plates.
After 72 h of culture, cells were washed and evaluated by FACS Calibur for
(A) CD8+ and (B) CD4+ T-cell expression and CFSE dilution. Data
represent the stimulation indices of the CD8 and CD4T-cells in the
presence of neutralizing Abs as compared to the control (T:APC + anti-CD3
Ab) condition). The data are represented such that the baseline value is 1
and all other values are adjusted relative to the baseline. Data presented
are representative of splenocytes obtained from eight WT, six PD-L1−/−,
and six PD-L2−/− mice with least three separate experiments and each
experiment comprising duplicates or triplicates of the given neutralizing Ab
condition. Signiﬁcant differences between sample means are indicated as
*p ≤ 0.05, **p ≤ 0.01 as compared to the baseline condition.
reduction in proliferation using anti-CD80 (on APC and/or T-
cells) Ab (p ≤ 0.05), a signiﬁcant decrease in proliferative capacity
was observed when anti-PD-L1 (T-cells only) Ab was also used
(p ≤ 0.01; Figure 5B). However, again, no increase in CD4+ pro-
liferation was observed withWT cells in the presence of anti-PD-1
Ab as was observed in Figure 2B. Overall, these data demonstrate
that the dominant CD28/CD80 co-stimulatory pathway observed
in WT and PD-L2−/− mice depends on co-expression of PD-L1,
and the current experiments suggest that its expression need be
on APCs and T-cells.
On the other hand, different co-stimulatory molecules seem
to play a compensatory role when the APCs lacked PD-L2. The
increased proliferation when anti-PD-1 Ab was used with WT T
andWTAPCs (Figure 2A) was lost in CD8+ T-cells when the same
neutralizing Ab was used in the case of WT T-cells co-cultured
with PD-L2−/− APCs. Neutralizing CD28 and CD80 individually
or combined, led to a decreased proliferation, both in the CD8+
and CD4+ T-cells (Figures 6A,B, respectively), indicating that
in the absence of PD-L2, CD28/CD80 stimulatory interactions are
dominant. Collectively, the data indicate that absence of PD-L2 on
APCs leads to an over-riding CD28/CD80 interaction that sends
positive co-stimulatory signals, leading to increased proliferative
capacities of the CD4+ T cells obtained from MCAO-subjected
WT mice. These data again are in agreement with the need for
co-expression of PD-L1 for expression of the CD28/CD80 co-
stimulatory pathway.
In lieu of the dissimilar proliferative trend exhibited by the
WT T-cells when co-cultured with PD-L1−/− APCs, it became
important to characterize the changes in PD-L1 andPD-L2 expres-
sion on various splenic immune cell types in the WT mice,
post-MCAO. In our previous publication (Bodhankar et al., 2013),
we demonstrated an increase in the total PD-L2 expression in
splenocytes of the PD-L1−/− mice as compared to the WT mice,
making a case for a plausible PD-1/PD-L2 co-inhibitory inter-
actions. We also demonstrated that the expression levels of total
PD-L1 in both theWT and PD-L2−/− mice remained similar after
MCAO. Hence, splenocytes from sham- and MCAO-subjected
WT mice were isolated and the percent expression of PD-L1 and
PD-L2 on various immune cell types was determined by ﬂow
cytometry. It is known that PD-L1 has much broader expression
pattern than PD-L2 and it is also characterized to be present on
T-cells in addition to APCs. Hence, we also evaluated PD-L1 and
PD-L2 expression on T-cells. The PD-L1 expression was signif-
icantly increased on the CD8+ T-cells (p ≤ 0.01) with a trend
towards increased expression in the CD4+ T-cells, after stroke
in WT splenocytes (Figure 7C). Even if the T-cells (CD4+ and
CD8+ T-cells) demonstrate an increase in expression of PD-L2
after stroke (Figure 7D), the level of expression is only a frac-
tion compared to that of PD-L1 on T-cells. Results upon assessing
the expression of PD-L1 on the classic APCs demonstrated that
the expression of PD-L1 increased signiﬁcantly (p ≤ 0.05) only
on CD19+ B-cells with a trend towards increased expression
on CD11c+ dendritic cells (Figure 7A). There was, however,
no change in the PD-L1 expression on the CD11b+ monocytes
after MCAO as compared to levels expressed in spleens of sham-
treated WT mice. Similarly, when the expression levels of PD-L2
were assessed on the classic APCs, its expression was signiﬁcantly
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increased on the CD19+ B cells (p ≤ 0.01) and CD11b+ mono-
cytes (p ≤ 0.01), with a trend in increased expression on the
CD11c+ DCs (Figure 7B). Thus, the abundance of expression
of PD-L1 on the CD8+ and likely the CD4+ T-cells justiﬁes the
decrease in the proliferative responses of the WT T-cells upon
co-culture with PD-L1−/− APCs in presence of anti-PD-L1 Ab
(CD4+ T-cells; Figure 5B) and anti-PD-1 + anti-PD-L1 and
anti-CD80 + anti-PD-L1 conditions (CD8+ T-cells; Figure 5A).
Overall, these results indicate that the presence of PD-L1 on T-
cells is as crucial as it is on the APCs, to elicit its functions after
stroke.
BREGS DECREASE INFARCT VOLUMES IN MALE PD-L2−/− MICE, BUT
ARE DISPENSABLE WHEN TRANSFERRED TO PD-L1−/− MICE 4 H
AFTER MCAO
As demonstrated in Figures 6A,B and 7B, the presence of PD-L2
on classic APCs is crucial. Moreover, as elucidated in Figure 7B,
PD-L2 expression was signiﬁcantly increased on CD19+ B cells.
Also, our previous study (Bodhankar et al., 2013) demonstrated
that even though the PD-L1−/− and PD-L2−/− mice had smaller
total infarct volumes compared to the WT mice, the pro-
inﬂammatory status as far as inﬁltrating cells in the brains was
the lowest in the PD-L1−/− as compared to both the WT and
PD-L2−/− mice. Also, the PD-L2−/− mice had an intermediary
pro-inﬂammatory status, with immune parameters trending to
be more like the WT mice rather than that like PD-L1−/− mice.
FIGURE 6 | Presence of PD-L1 onAPCs is as important as it is onT-cells,
while expression of PD-L2 is crucial on APCs ofWT mice, subjected to
MCAO.T-cells were puriﬁed, by negative sort, from the spleens of
MCAO-subjected WT mice, by labeling with speciﬁc microbeads and
separating on the AutoMACSTM.The puriﬁedT-cells were CSFE-labeled and
then cultured with non-T-cells from PD-L2−/− mice at a 1:1 ratio (T:APC) in
the presence of anti-CD3 antibody (2.5 μg/mL; baseline) and other
neutralizing Abs (10 μg/mL) to co-stimulatory molecules, in 96-well plates.
After 72 h of culture, cells were washed and evaluated by FACS Calibur for
A CD8+ and (B) CD4+ T-cell expression and CFSE dilution. Data represent
the stimulation indices of the CD8 and CD4T-cells in the presence of
neutralizing Abs as compared to the control (T:APC + anti-CD3 Ab)
condition). The data are represented such that the baseline value is 1 and all
other values are adjusted relative to the baseline. Data presented are
representative of splenocytes obtained from eight WT, six PD-L1−/− and
six PD-L2−/− mice with least three separate experiments and each
experiment comprising duplicates or triplicates of the given neutralizing Ab
condition. Signiﬁcant differences between sample means are indicated as
*p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001 as compared to the baseline
condition.
FIGURE 7 | Characterization of PD-L1 and PD-L2 expression onT-cells
and antigen presenting cells ofWT splenocytes, post-MCAO.
Splenocytes from sham- and MCAO-subjected WT mice were harvested
96 h after MCAO (60 min) and assessed for expression. (A) PD-L1 and (B)
PD-L2 on APCs; gated on CD19+, CD11b+, and CD11c+ cells. (C) PD-L1
and (D) PD-L2 on gated CD4+ and CD8+ T-cells. Values represent mean
numbers (±SEM) of indicated cell subsets, gated on live leukocytes (by PI
exclusion) from 4–5 mice of each group, from two separate experiments.
Statistical analysis was performed using Student’s t-test. Signiﬁcant
differences between sample means are indicated as *p ≤ 0.05 and
**p ≤ 0.01 as compared to the sham-treated WT mice.
Recently, we demonstrated (Bodhankar et al., 2014) that transfer
of IL-10+ B cells markedly reduced infarct volumes in WT recip-
ient mice when given 4 h after MCAO. Hence, in an attempt to
discern the regulatory mechanism pertaining to these PD-ligands,
we hypothesized that similar to WT recipients of IL-10+ B cells
(regulatory B cells; Bregs), 4 h after MCAO, the PD-L2−/− recipi-
ents of IL-10+ B cells, would be protected, thus indicating that the
presence of PD-L2 on B cells is indispensable for the B cells’ ability
to mediate its immune-modulatory actions. Thus, we examined
the relative contribution of PD-L1 and PD-L2, when present on
the Bregs, in mediating their protective properties.
B cells obtained from spleens of IL-10-GFP reporter mice were
puriﬁed by negative selection and cultured in vitro for 48 h in pres-
ence of LPS. This in vitro culture enriched the B cells to produce
high amounts of IL-10 cytokine. These IL-10-enriched Bregs were
transferred to PD-L1−/− and PD-L2−/− recipients. As shown in
Frontiers in Cellular Neuroscience www.frontiersin.org August 2014 | Volume 8 | Article 228 | 8
Bodhankar et al. PD-Ligands differentially regulate experimental stroke
Figure 8A, PD-L1−/− mice that received IL10+ B-cells (n = 8)
4 h after MCAO exhibited no differences in the infarct volumes in
each of the cortex, striatum and hemisphere regions after 60 min
MCAO followed by 96 h of reperfusion compared to no-cell trans-
ferred vehicle (RPMI) controls (n = 7). However, when IL-10+
B-cells were transferred to the PD-L2−/− mice (n = 10) 4 h after
MCAO, therewas as signiﬁcant reduction in cortical (p≤ 0.05) and
total hemisphere (p ≤ 0.01) infarct volumes after 60 min MCAO
followed by 96 h of reperfusion compared to no-cell transferred
vehicle (RPMI) controls (n = 11). Representative cerebral sections
fromPD-L1−/− and PD-L2−/− mice treated with RPMI or IL10+
B-cells are shown in Figures 8A,B.
We further ascertained whether differences in surface expres-
sion of CD1dhiCD5+ on B cells (Bregs) in the PD-L1−/− or
PD-L2−/− mice as compared to WT mice might reﬂect the dif-
ferences in protection in these strains, after the transfer of Breg
cells. We assessed the expression of a recently characterized regu-
latory B-cell sub-population, known as the CD1dhiCD5+CD19+
Bregs (Bodhankar et al., 2011) which is known to effectively down-
regulate T-cell activation by virtue of their IL-10 production
(Yanaba et al., 2008).We determined the CD1dhiCD5+ expression
(Figure 8C) and IL-10-secretion by B cells (Figure 8D). Spleno-
cytes from sham- and MCAO-subjected WT, PD-L1−/− and
PD-L2−/− mice were obtained and the expression of cell surface
molecules, CD1d and CD5, was determined on CD19+ B cells
(Figure 8C) as was the intracellular IL-10 expression (Figure 8D).
As demonstrated in Figures 8C,D a signiﬁcant increase in the
percentage of not only CD1dhiCD5+CD19+ Bregs but also the
production of IL-10 by this cell sub-type was observed to be
already present in the PD-L1−/− mice as compared to both WT
(p ≤ 0.05), and the PD-L2−/− (p ≤ 0.05) mice. Thus, these
results demonstrate that Bregs decrease infarct volume in male
PD-L2−/− mice, but are dispensable and cannot further affect the
ongoing infarction process when transferred 4 h after MCAO to
PD-L1−/− knockout mice that already have increased levels of
Breg cells.
DISCUSSION
Stroke remains the third leading cause of death in adultsworldwide
and the most frequent cause of permanent disability in the world
(Donnan et al., 2008). Although underlying mechanisms have not
been completely unraveled, that ischemia evokes inﬂammatory
FIGURE 8 | Bregs decrease infarct volumes in male PD-L2−/− mice, but
are dispensable when transferred to PD-L1−/− mice 4 h after MCAO.
(A) Intravenous transfer of 5 million IL10+ B-cells 4 h after surgery to induce
MCAO in PD-L1−/− mice 96 h following 60 min of MCAO compared to
intravenous transfer of RPMI vehicle (no cells) and its representative
2,3,5-triphenyltetrazolium chloride (TTC) stained cerebral sections 96 h
following 60 min of MCAO. (B) Intravenous transfer of 5 million IL10+ B-cells
4 h after surgery to induce MCAO in PD-L2−/− mice 96 h following 60 min of
MCAO compared to intravenous transfer of RPMI vehicle (no cells) and its
representative TTC stained cerebral sections 96 h following 60 min of MCAO.
Signiﬁcance values represent mean ± SEM. *p < 0.05, **p < 0.01.
Splenocytes from sham-treated and MCAO-subjected WT, PD-L1−/− and
PD-L2−/− mice were harvested 96 h after MCAO (60 min) and assessed for
expression of: (C) CD1dhiCD5+CD19+ (Breg) cells and (D) IL-10 production
by gated Breg cells. Data are representative of two independent experiments
with spleens processed from four to ﬁve individual mice (mean ± SEM).
Signiﬁcant differences between sample means are indicated (*p ≤ 0.05
compared to the PD-L1−/− mice, post MCAO). Signiﬁcant differences within
the strains are indicated (#p ≤ 0.05 and ###p ≤ 0.001 as compared to its
respective sham-treated counterparts).
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responses has been well characterized. Besides the well-deﬁned
players of innate immunity, which inﬁltrate the damaged brain
area after ischemic stroke, our past studies demonstrated that
the T-cells from blood and lymph nodes secrete increased lev-
els of inﬂammatory cytokines after activation following ischemic
stroke (Offner et al., 2006). Also a signiﬁcant increase in T lym-
phocytes in the ischemic hemisphere has been demonstrated at
3 days post-reperfusion (Gelderblom et al., 2009). Our group has
also demonstrated using SCID mice that T lymphocytes have a
damaging effect on early ischemic brain injury (Hurn et al., 2007).
However, the mechanisms of T-cell-mediated brain injury fol-
lowing stroke are currently unclear. It is not clear whether the
activation of T-cells follows the classical antigen-dependent path-
way or if the inﬁltration into the brain following stroke is too rapid
to follow the classical pathway. A recent study by Kleinschnitz et al.
(2010) demonstrated that the antigen-dependent activation of T-
cells is not required for them to contribute substantially to the
infarct volume present at 22 h after ischemic stroke. However,
several studies also demonstrate that previously activated T lym-
phocytes, i.e., due to preexisting infection, cardiovascular disease
(Guzik et al., 2007; Andersson et al., 2010) or even in autoimmune
disease (Ren et al., 2012) cause additional damage in the brain,
following ischemic stroke. Furthermore, two more studies indi-
cate that administration of the recombinant TCR ligand, RTL551
linked to a CNS antigen (which blocks classical antigen-dependent
T-cell activation), resulted in a reduced infarct volume following
ischemic stroke (Subramanian et al., 2009; Dziennis et al., 2011).
These ﬁndings suggest that an adaptive immune response to brain
antigens occurred following stroke, and that classical T-cell activa-
tion may indeed have contributed to post-ischemic brain damage.
Moreover, tolerance against brain antigens by mucosal adminis-
tration of a CNS myelin antigen before stroke has been reported
to improve outcome after stroke (Becker et al., 1997; Frenkel
et al., 2005; Gee et al., 2008), further suggesting that antigen-
dependent lymphocyte activation occurs following stroke, and
that it contributes to brain injury. However, the mechanism(s) of
antigen-independent T-cell “activation” within hours after stroke
are currently unknown.
T-cell activation involves the B7 family of co-stimulatory
molecules, which provide pivotal stimulatory or inhibitory sig-
nals and a balance between these signals is required for effective
immune responses to various stimuli. Our past study (Ren et al.,
2011) on one hand demonstrated that PD-1 is crucial in medi-
ating protection in ischemic stroke, but on the other hand, our
subsequent study (Bodhankar et al., 2013) involving PD-ligand
knockout mice demonstrated the stimulatory role of the PD-
ligands in ischemic stroke. Hence, it was necessary to investigate
the nature of interactions between PD-1 and both its ligands for
understanding the susceptibility, pathogenic mechanisms, and
protection afforded after ischemic stroke. In another previous
study (Bodhankar et al., 2013), we demonstrated that WT and
PD-L2−/− mice demonstrated a signiﬁcantly increased expres-
sion of the co-stimulatory molecule, CD80 (B7.1) on the CD11c+
dendritic cells and by the CD11b+ monocytes as compared to
that in the PD-L1−/− mice, after MCAO. Also, the expression
levels of total PD-L1 on splenocytes of both the WT and PD-
L2−/− remain similar after MCAO. Thus, we speculated that the
CD80-CD28 interaction overrides the CD80-CTLA-4 or CD80-
PD-L1 interactions leading to T-cell activation in the WT and
PD-L2−/− mice. Conversely, low CD80 expression by the APCs
in PD-L1−/− mice suggested T-cell signaling through CTLA-4,
leading to a suppressor phenotype. Also an increase in the total
PD-L2 expression in the PD-L1−/− mice as compared to the WT
mice, made a case for a plausible PD-1/PD-L2 co-inhibitory inter-
action in the absence of PD-L1. Hence the purpose of this study
was to verify the aforementioned hypotheses. In order to do so, we
ﬁrst determined the change in the expression levels of some of the
T-cell-related major players of the co-stimulatory pathway in WT
mice, post-stroke. CD28 has a predominant role during initial T-
cell activation while ICOS regulates antigen-experienced T-cells,
but CD28 and ICOS synergize to promote the activation of T-
cell responses (Greenwald et al., 2005). Also, CTLA-4, an immune
inhibitory receptor within the CD28 family of co-stimulatory
molecules (Salomon and Bluestone, 2001; Greenwald et al., 2005;
Peggs et al., 2009), shares its ligands B7-1 and B7-2 with CD28 but
binds themwithdifferential kinetics (Riley and June,2005). CTLA-
4 is induced in activated T-cells and inhibits T-cell activation by
engaging speciﬁc signaling pathways and by out-competing the
positive co-stimulatory receptor CD28 (Salomon and Bluestone,
2001; Engelhardt et al., 2006). It is also constitutively expressed in
FoxP3+ Tregs (Read et al., 2000; Annunziato et al., 2002). Hence,
the levels of expression of these three players were determined on
splenocytes from sham- and MCAO-subjected WT mice. But as
demonstrated in Figures 1A–C, the expression levels of CD28 are
signiﬁcantly increased and those of CTLA-4 were reduced; how-
ever, the expression of ICOS did not change between sham and
MCAO-subjected mice until day 3 post-stroke. Thus, it appeared
as though themolecules of the CD80/CD28, CTLA-4, and the PD-
1/PD-L pathway are more critical than others in ischemic stroke.
Therefore, we next focused on these co-stimulatory players and
how the preferential neutralization of each these players inﬂu-
enced the proliferative capacities of the T-cells of the WT mice,
post-stroke.
Our speculation of the over-riding association between CD80
and CD28 seems to hold true, more so, in case of CD8+ T-cells
of WT mice as demonstrated in Figure 2A because the prolifer-
ative capacities of CD8+ T-cells were signiﬁcantly decreased in
presence of anti-CD80 and anti-CD80 + anti-CD28 neutralizing
Abs, whereas neutralizing PD-1 signiﬁcantly increased prolifera-
tion. In support of our ﬁndings, studies involving intrahepatic
virus-speciﬁc T-cell dysfunction, particularly in HCV-infected
liver also demonstrate that T-cell function can be synergisti-
cally reversed by combined PD-1/CTLA-4 blockade in vitro in
a CD4-independent and CD28-dependent manner (Nakamoto
et al., 2009). The study demonstrated that functional response
to PD-1/CTLA-4 blockade was abolished in HCV-speciﬁc CD8+
T-cells by CD28-depletion suggesting that immune exhaustion
at the site of antigen expression may be reversed by combined
inhibitory receptor blockade. In another study, it has also been
suggested that since PD-L1 also interacts with B7-1 (Butte et al.,
2008), both anti-PD-L1 and anti-CTLA-4 can increase the acces-
sibility of B7-1 to CD28 (Parry et al., 2005). Thus, our ﬁndings
in this current study are in synchrony with the aforementioned
studies, since as demonstrate in Figures 2A,B CD8+ T-cells seem
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to be impacted with CD28/CD80 interactions while CD4+ T-cells
with PD-1/PD-L2 interactions.
PD-L1 and PD-L2 are known tomediate both positive and neg-
ative signals. Contrary to the best-characterized inhibitory role for
PD-L1, a stimulatory role has been suggested in a number of recent
studies. For example, transgenic over-expression of PD-L1onpan-
creatic beta cells enhanced autoimmunity instead of suppressing it
(Subudhi et al., 2004). As a result of PD-L1 over-expression in beta
cells, CD8+ T-cell proliferation was enhanced and immunologi-
cal tolerance was broken, as mice developed spontaneous diabetes
(Subudhi et al., 2004). In yet another study (Waisman and Yogev,
2009), an unexpected beneﬁcial effect from PD-L1−/− DC was
demonstrated where intra-cerebral microinjections resulted in
amelioration of subsequent EAE (Waisman andYogev, 2009). Fur-
thermore, our results in Figures 3A,B also demonstrate that the
most impact on the proliferative capacities of both the CD8+ and
CD4+ T cells in PD-L1−/− mice, after stroke, was when neutraliz-
ing Abs to CD80 + CTLA-4 and PD-1 + PD-L2 were used. These
data indicate that in the absence of PD-L1, with the decreased
expression of CD80, CTLA-4/CD80 interactions become preva-
lent, leading to the induction of inhibitory signals in T cells. We
thus propose a working model based on all our results obtained
thus far (Figure 9).
Several lines of work have also suggested that the broad expres-
sion of PD-L1 in lymphoid and non-lymphoid organs and the
more restricted, but overlapping, expression of PD-L2 in DC
and macrophages may explain, in part, how these B7 family
members can have overlapping and/or distinct biological func-
tions (Loke and Allison, 2003). Several animal models suggest
that distinct functions could be elicited by PD-L1 and PD-L2
(Liang et al., 2006; Zhu et al., 2006). Recent data suggest higher
afﬁnity binding of PD-L2 to PD-1 (Lazar-Molnar et al., 2008).
Hence, the ability of PD-L1 and PD-L2 to compete for PD-
1 might be important to consider especially on cells that are
known to express both ligands, such as APCs, but also in tis-
sues undergoing inﬂammation (Greenwald et al., 2005). However,
differences remain relative to binding kinetics and expression lev-
els. In general, PD-L2 is expressed late, and at lower levels. Data
suggest that the cytokine environment may have an important
role in differentially regulating PD-L1 and PD-L2 expression and
modulating inﬂammatory responses in the lung microenviron-
ment. In fact, studies also show that PD-L1 and PD-L2 have
important but opposing roles inmodulating and polarizing iNKT-
cell function in airway hyper-responsiveness (AHR) and airway
inﬂammation (Akbari et al., 2010). Shin et al. (2005) have shown
that PD-L2, but not PD-L1 was found to elicit direct activating
effects on DCs and this effect is supposed to enhance immune
responses. However, the concurrent presence of PD-L1 on the
same cell prevented this activating effect of PD-L2 due to compe-
tition with PD-1 availability (Ghiotto et al., 2010). Hence, these
studies support our ﬁndings that in the absence of PD-L1, the
PD-1/PD-L2 pathway is dominant and pivotal in affecting the pro-
liferative responses (Figures 3A,B). At the same time, only subtle
changes in proliferative capacities were exhibited by both CD8+
and CD4+ T-cells obtained from PD-L2−/− mice (Figures 4A,B),
wherein PD-L1 expression is intact. These data imply that a dom-
inant pathogenic role is played by PD-L1 in ischemic stroke as
compared to the other PD-1 ligand, namely PD-L2. Interestingly,
FIGURE 9 | Proposed model for the role of CD28, CTLA-4, CD80, and
the PD-1/PD-L pathway in mice after ischemic stroke. The following
mechanisms of action for the various co-stimulatory molecules belonging
to the B7 family are postulated. The afﬁnity of CD80 for CTLA-4, PD-L1,
and CD28 are kd = 0.4, 1.4, and 4.0 μM, respectively. Thus, at
homeostatic levels, (A) PD-L1 competes with CTLA-4 for CD80 binding,
thus providing in concert with MHC molecules a non-activating signal
that promotes naïve T-cell survival, while simultaneously suppressing
T-cell responses by outcompeting signaling through CD80/CD28. When
stroke is induced in (B) WT and (C) PD-L2−/− mice, the level of CD80
expression is signiﬁcantly increased, enhancing T-cell signaling through
CD28 and further promoting T-cell activation resulting in an effector
phenotype. However, when stroke is induced in the absence of PD-L1.
(D) PD-L1−/− mice, with low CD80 expression and without PD-L1 to
compete with CTLA-4, T-cell signaling results through CTLA-4. Also,
MCAO-subjected PD-L1−/− mice exhibit signiﬁcantly higher levels of
both PD-1 and PD-L2, resulting in their prominent interactions. Thus, we
propose that the CD80/CTLA-4 and PD-1/PD-L2 eventually lead to a
suppressor phenotype. hi high expression, lo low expression, med
medium expression, CTLA-4 cytotoxic T lymphocyte-associated antigen-4,
TCR T-cell receptor, MHC Major Histocompatibility complex (adapted from
Zozulya et al., 2010).
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our study further demonstrated the stimulatory role of PD-L1,
especially when WT T-cells were co-cultured with PD-L2−/−
APCs, in that the presence of PD-L1 on T cells is critical as indi-
cated by the fact that when CD80 (APC-expressed) and PD-L1
(expressed on T-cells in this scenario) neutralizing Abs were used,
a decrease in the proliferative capacities of the CD8 (Figure 6A)
and CD4 (Figure 6B) T-cells was demonstrated, thus implicat-
ing these factors as co-stimulatory molecules. Furthermore, when
we extended our studies to decipher the cell type responsible to
mediate the critical function of immune-suppression or immuno-
activation by each of PD-ligands, post-stroke, we demonstrated
a signiﬁcant increase in PD-L2 on splenic APCs of WT mice
(Figure 7B) especially CD19+ B cells. Also, lower infarct volumes
in the PD-L2−/− recipients upon reconstitution with PD-L2+
IL-10-enriched Bregs were demonstrated. Thus, the PD-L2−/−
recipients are protected like the WT mice that receive IL-10+
Bregs, 4 h after MCAO (Bodhankar et al., 2014). However, no
difference in the infarct volumes was demonstrated in the PD-
L1−/− recipients of PD-L1+Bregs. Collectively, these ﬁndings
indicate the crucial role of the PD-L2 on the APCs, especially
Breg cells (Figures 6, 7B and 8A), in contrast to a dispens-
able role of PD-L1 on the Bregs. In the context of possible
therapy, the data support the prediction that treatment with anti-
PD-L1 Ab would likely be beneﬁcial for nullifying CD8+ and
CD4+ T-cell effects by reducing the co-stimulatory CD28/CD80
interactions and enabling co-inhibitory PD-1/PD-L2 and CTLA-
4/CD80 interactions. On the other hand, neutralization of PD-L1
would appear to reduce or obviate regulatory effects of Breg cells
on stroke. Subsequent experimentation will thus be required to
sort out the safety and relative efﬁcacy of antibody blockade of
PD-L1 vs. transfer of Breg cells in the presence of functional
PD-L1.
In summary, the current study conclusively demonstrates for
the ﬁrst time that PD-L1 and PD-L2 have distinct roles in con-
trolling the T-cell activation after ischemic stroke. CD80/CD28
interactions played a prominent regulatory role for the CD8+
T-cells and the PD-1/PD-L2 interactions were dominant in con-
trolling the CD4+ T-cell responses in WT mice, after stroke. A
suppressive phenotype in PD-L1 deﬁcient mice was attributed to
CD80/CTLA-4 and PD1/PD-L2 interactions. PD-L2 was crucial
in modulating CD4+ T-cell responses, whereas PD-L1 regulated
both CD8+ and CD4+ T-cells. To establish the contribution
of PD-L1 and PD-L2 on regulatory B-cells (Bregs), infarct vol-
umes were evaluated in male PD-L1- and PD-L2-deﬁcient mice
receiving IL-10+ B-cells 4 h after MCAO. PD-L2- but not PD-
L1-deﬁcient recipients of IL-10+ B-cells had markedly reduced
infarct volumes, indicating a regulatory role of PD-L2 on Bregs.
Overall, it is apparent that these pathways provide redundant
positive and negative signals and that there is some hierarchy
in the orchestration of their signals. The current study provides
insights into mechanisms of T-cell activation in ischemic stroke,
thus exhibiting the potential for therapeutic intervention for con-
trolling T-cell responses. Our results clearly imply that PD-L1
and PD-L2 differentially control induction of T- and Breg-cell
responses afterMCAO, thus suggesting that selective targeting PD-
L1 and PD-L2 might represent a valuable therapeutic strategy in
stroke.
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